Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram

British Journal of Pharmacology

Volumn 121, Issue 6, 1997, Pages 1150-1154

  Santamaria, Luis F ^a   Palacios, Jose Maria ^a   Beleta, Jorge ^a  

^a S A Research Center ^*  (Spain)

Author keywords

Eotaxin; Human eosinophil; PDE 4; Phosphodiesterase inhibitor; Rolipram

Indexed keywords

CD11B ANTIGEN; L SELECTIN; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ARTICLE; CELL SURFACE; EOSINOPHIL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE MIGRATION; NORMAL HUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CHEMOKINES, CC; CHEMOTAXIS; CYTOKINES; ENZYME INHIBITORS; EOSINOPHILS; HUMANS; L-SELECTIN; MACROPHAGE-1 ANTIGEN; PYRROLIDINONES; ROLIPRAM; UP-REGULATION;

EID: 0030795747     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701243     Document Type: Article

References (48)

1. BAGGIOLINI, M., DEWALD, B. & MOSER, B. (1994). Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol., 55, 97-179.
2. BANNER, K.H. & PAGE, C.P. (1995). Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs. Br. J. Pharmacol, 114, 93-98.
3. BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 76, 725-748.
4. BOURNE, H.R., LICHTENSTEIN, L.M., MELMON, K.L., HENNEY, C.S., WEINSTEIN, Y. & SHEARER, G.M. (1974). Modulation of inflammation and immunity by cyclic AMP. Science, 174, 19-28.
5. COLLINS, P.D., MARLEAU, S., GRIFFITHS-JOHNSON, D.A., JOSE, P.J. & WILLIAMS, T.J. (1995). Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J. Exp. Med., 182, 1169-1174.
6. DAHINDEN, C.A., GEISER, T., BRUNNER, T., VON TSCHARNER, V., CAPUT, D., FERRARA, P., MINTY, A. & BAGGIOLINI, M. (1994). Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J. Exp. Med., 179, 751-756.
7. DAUGHERTY, B.L., SICILIANO, S.J., DE MARTINO, J.A., MALKOWITZ, L., SIROTINA, A. & SPRINGER, M.S. (1996). Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J. Exp. Med., 183, 2349-2354.
8. DENT, G., GIEMBYCZ, M.A., EVANS, P.M., RABE, K.F. & BARNES, P.J. (1994). Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther., 271, 1167-1174.
9. DETMERS, P.A., LO, S.K., OLSEN-EGBERT, E., WALZ, A., BAGGIOLINI, M. & COHN, Z.A. (1990). Neutrophil-activating protein 1/ interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b/CD18 on human neutrophils. J. Exp. Med., 171, 1155-1162.
10. DIAMOND, M.S., STAUNTON, D.E., DE FOUGEROLLES, A.R., STACKER, S.A., GARCIA AGUILAR, J., HIBBS, M.L. & SPRINGER, T.A. (1990). ICAM-1 (CD54): a counterreceptor for Mac-1 (CD11b/CD18). J. Cell. Biol., 111, 3129-3139.
11. DRANSFIELD, I., BUCKLE, A-M. & HOGG, N. (1990). Early events of the immune response mediated by leukocyte integrins. Immunol. Rev., 114, 29-44.
12. ELSNER, J., HÖCHSTETTER, R., KIMMIG, D. & KAPP, A. (1996). Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur. J. Immunol., 26, 1919-1925.
13. GARCIA-ZEPEDA, E.A., ROTHENBERG, M.E., OWNBEY, R.T., CELESTIN, J., LEDER, P. & LUSTER, A.D. (1996). Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Med., 2, 449-456.
14. GIEMBYCZ, M.A. (1992). Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol., 43, 2041-2051.
15. 2-type response. Immunity, 4, 1-14.
16. GRIFFITHS-JOHNSON, D.A., COLLINS, P.D., ROSSI, A.G., JOSE, P.J. & WILLIAMS, T.J. (1993). The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lungs in vivo. Biochem. Biophys. Res. Commun., 197, 1167-1172.
17. HALL, I.P. (1993). Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br. J. Clin. Pharmacol., 35, 1-7.
18. HALLSWORTH, M.P., GIEMBYCZ, M.A., BARNES, P.J. & LEE, T.H. (1996). Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br. J. Pharmacol., 117, 79-86.
19. HANIFIN, J.M., CHAN, S.C., CHENG, J.B., TOFTE, S.J., HENDERSON, W.R., KIRBY, D.S. & WEINER, E.S. (1996). Type 4 phosphodiesterase inhibitor have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol., 107, 51-56.
20. HANSEL, T.T., DE VRIES, I.J., IFF, T., RIHS, S., WANDZILAK, M., BETZ, S., BLASER, K. & WALKER, K. (1991). An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J. Immunol. Methods., 145, 105-110.
21. HATZELMANN, A., TENOR, H. & SCHUDT, C. (1995). Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol., 114, 821-831.
22. HUGHES, B., HOWAT, D., LISLE, H., HOLBROOK, M., JAMES, T., GOZZARD, N., BLEASE, K., HUGHES, P., KINGABY, R., WARRELOW, G., ALEXANDRE, R., HEAD, J., BOYD, E., EATON, M., PERRY, M., WALES, M., SMITH, B., OWENS, R., CATTERALL, C., LUMB, S., RUSSELL, A., ALLEN, R., MERRIMAN, M., BLOXHAM, D. & HIGGS, G. (1996). The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol., 118, 1183-1191.
23. JOSE, P.J., GRIFFITHS-JOHNSON, D.A., COLLINS, P.D., WALSH, D.T., MOQBEL, R., TOTTY, N.F., TRUONG, O., HSUAN, J.J. & WILLIAMS, T.J. (1994). Eotaxin: a potent eosinophil chemoattractant cytokine detected in guinea pig model of allergic airways inflammation. J. Exp. Med., 179, 881-887.
24. KAMMER, G.M. (1988). The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today, 9, 222-229.
25. KISHIMOTO, T.K., JUTILA, M.A., BERG, E.L. & BUTCHER, E.C. (1989). Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science, 245, 1238-1241.
26. LAGENTE, V., PRUNIAUX, M-P., JUNIEN, J-L. & MOODLEY, I. (1995). Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med., 151, 1720-1724.
27. LEIFERMAN, K.M. (1994). Eosinophils in atopic dermatitis. J. Allergy Clin. Immunol., 94, 1310-1317.
28. MOORE, A.R. & WILLOUGHBY, D.A. (1996). The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol., 101, 387-389.
29. NICHOLSON, C.D. & SHAHID, M. (1994). Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes their potential utility in the therapy of asthma. Pulmonary Pharmacol, 7, 1-17.
30. PALFREYMAN, M.N. (1995). Phosphodiesterase type IV inhibitors as antiinflammatory agents. Drugs of the Future, 20, 793-804.
31. PONATH, P.D., QIN, S., RINGLER, D.J., CLARK-LEWIS, I., WANG, J., KASSAM, N., SMITH, H., SHI, X., GONZALO, J-A., NEWMAN, W., GUTIERREZ-RAMOS, J-C. & MACKAY, C.R. (1996). Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Invest., 97, 604-612.
32. QIN, S., LA ROSA, G., CAMPBELL, J.J., SMITH-HEATH, H., KASSAM, N., SHI, X., ZENG, L., BUTCHER, E.C. & MACKAY, C.R. (1996). Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur. J. Immunol., 26, 640-647.
33. ROT, A., KRIEGER, M., BRUNNER, T., BISCHOFF, S.C., SCHALL, T.J. & DAHINDEN, C.A. (1992). RANTES and macrophage inflammatory protein 1a induce the migration and activation of normal human eosinophil granulocytes. J. Exp. Med., 176, 1489-1495.
34. ROTHENBERG, M.E., LUSTER, A.D. & LEDER, P. (1995a). Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. U.S.A., 92, 8960-8964.
35. ROTHENBERG, M.E., LUSTER, A.D., LILLY, C.M., DRAZEN, J.M. & LEDER, P. (1995b). Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J. Exp. Med., 181, 1211-1216.
36. SANZ, M.J., PONATH, P.D., MACKAY, C.R., NEWMAN, W., JOSE, P.J., LOBB, R.R., MIYASAKA, M., WILLIAMS, T.J. & NOURSHARGH, S. (1996). Human eotaxin induces eosinophil accumulation in rat skin which is dependent on both VCAM-1 and ICAM-1. In Juan March Workshop on Vascular Endothelium and Regulation of Leukocyte Traffic, Madrid, (Abstract): Centre for International Meetings on Biology.
37. SOUNESS, J.E., MASLEN, C., WEBBER, S., FORSTER, M., RAEBURN, D., PALFREYMAN, M.N., ASHTON, M.J. & KARLSSON, J-A. (1995). Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br. J. Pharmacol., 115, 39-46.
38. SPRINGER, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell, 76, 301-314.
39. SRIRAMARAO, P., VON ANDRIAN, U.H., BUTCHER, E.C., BOURDON, M.A. & BROIDE, D.H. (1994). L-selectin and very late antigen-4 integrin promote eosinophil rolling at physiological shear rates in vivo. J. Immunol., 153, 4238-4246.
40. TAKAHASHI, K., SAWASAKI, Y., HATA, J., MUKAI, K. & GOTO, T. (1990). Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev. Biol., 26, 265-274.
41. TEIXEIRA, M.M., ROSSI, A.G., WILLIAMS, T.J. & HELLEWELL, P.G. (1994). Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. J. Pharmacol., 112, 332-340.
42. TEIXEIRA, M.M., WILLIAMS, T.J. & HELLEWELL, P.G. (1995). Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo. Trends Pharmacol. Sci., 16, 418-423.
43. TORPHY, T., BARNETTE, M.S., HAY, D.W.P. & UNDERWOOD, D.C. (1994). Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environm. Health Perspect., 102, 79-84.
44. TORPHY, T. & UNDEM, B.J. (1991). Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax, 46, 512-523.
45. UGUCCIONI, M., LOETSCHER, P., FORSSMANN, U., DEWALD, B., LI, H., LIMA, S.H., LI, Y., KREIDER, B., GAROTTA, G., THELEN, M. & BAGGIOLINI, M. (1996). Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J. Exp. Med., 183, 2379-2384.
46. WALKER, C., RIHS, S., BRAUN, R.K., BETZ, S. & BRUIJNZEEL, P.L.B. (1993). Increased expression of CD11b and functional changes in eosinophils after migration across endothelial cell monolayers. J. Immunol., 150, 4061-4071.
47. WEBER, C., KITAYAMA, J. & SPRINGER, T.A. (1996). Differential regulation of β1 and β2 integrin avidity by chemoattractants in eosinophils. Proc. Natl. Acad. Sci. U.S.A., 93, 10939-10944.
48. WELLER, P.F. (1991). The immunobiology of eosinophils. New Engl. J. Med., 324, 1110-1118.